NCT00492050 · OUTCOME

Participants Ability to Collect Stem Cells After Treatment With Bortezomib and Rituximab

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia · Source last updated 2026-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 4 weeks

What was measured

Number of Participants who were able to collect stem cells successfully or unable to collect after treatment with bortezomib and rituximab.

Groups in this outcome

All Participants

Bortezomib 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily). Bortezomib: 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab: 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	37

Reported measurements

Participants Collected Successfully

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Participants	30	Not reported	Not reported	Not reported	Not reported

Participants Unable to Collect

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Participants	7	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
30
title
Participants Collected Successfully
categories
measurements
group Id
OG000
value
7
title
Participants Unable to Collect

denoms

counts
group Id
OG000
value
37
units
Participants

description

Number of Participants who were able to collect stem cells successfully or unable to collect after treatment with bortezomib and rituximab.

groups

description
Bortezomib 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily). Bortezomib: 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab: 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)
id
OG000
title
All Participants

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

4 weeks

title

Participants Ability to Collect Stem Cells After Treatment With Bortezomib and Rituximab

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice